title: Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
abstract: The expression of human SLFN11 was reported to sensitize cancer cells to DNA damaging agents. This study is to explore the epigenetic change and the function of SLFN11 in human colorectal cancer (CRC).
  
  
  
  Six CRC cell lines and 128 primary CRC samples were used.
  
  
  
  SLFN11 was methylated in 55.47% (71/128) of primary CRC. The expression of SLFN11 was regulated by promoter region methylation. Methylation of SLFN11 was significantly associated with age, poor 5-year overall survival and 5-year relapse-free survival (all p < 0.05). SLFN11 suppressed CRC cell growth both in vitro and in vivo and sensitized CRC cells to cisplatin.
  
  
  
  SLFN11 is frequently methylated in human CRC, and the expression of SLFN11 is regulated by promoter region methylation. Methylation of SLFN11 reduced the sensitivity of CRC cells to cisplatin.
authors.affiliation: Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.|Department of Pathology, The Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China.
authors.forename: Tao
authors.initials: T
authors.lastname: He
authors.affiliation: Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.|Medical College, NanKai University, Tianjin 300071, China.
authors.forename: Meiying
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.|Medical College, NanKai University, Tianjin 300071, China.
authors.forename: Ruipan
authors.initials: R
authors.lastname: Zheng
authors.affiliation: Department of Pathology, The Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China.
authors.forename: Shufang
authors.initials: S
authors.lastname: Zheng
authors.affiliation: Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.
authors.forename: Enqiang
authors.initials: E
authors.lastname: Linghu
authors.affiliation: Medical College, NanKai University, Tianjin 300071, China.
authors.forename: James G
authors.initials: JG
authors.lastname: Herman
authors.affiliation: Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing 100853, China.
authors.forename: Mingzhou
authors.initials: M
authors.lastname: Guo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D019175:DNA Methylation; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D011401:Promoter Regions, Genetic
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C576668:SLFN11 protein, human; D002945:Cisplatin
keywords: DNA damage repair; SLFN11; cisplatin; colorectal cancer; epigenetics; methylation